Bryn Mawr Capital Management’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26.8M | Sell |
222,405
-8,169
| -4% | -$943K | 1.3% | 12 |
|
|
2025
Q4 | $24.3M | Sell |
230,574
-12,118
| -5% | -$1.14M | 1.17% | 16 |
|
|
2025
Q3 | $20.4M | Buy |
242,692
+2,613
| +1% | +$215K | 1.01% | 19 |
|
|
2025
Q2 | $19M | Sell |
240,079
-2,982
| -1% | -$237K | 1.04% | 17 |
|
|
2025
Q1 | $21.8M | Buy |
243,061
+523
| +0.2% | +$48.8K | 1.31% | 15 |
|
|
2024
Q4 | $24.1M | Sell |
242,538
-7,319
| -3% | -$755K | 1.3% | 13 |
|
|
2024
Q3 | $28.4M | Sell |
249,857
-2,504
| -1% | -$297K | 1.53% | 11 |
|
|
2024
Q2 | $31.3M | Buy |
252,361
+5,549
| +2% | +$715K | 1.72% | 9 |
|
|
2024
Q1 | $32.6M | Buy |
246,812
+6,109
| +3% | +$753K | 1.85% | 7 |
|
|
2023
Q4 | $26.2M | Buy |
240,703
+13,339
| +6% | +$1.38M | 1.64% | 9 |
|
|
2023
Q3 | $23.4M | Buy |
227,364
+55,460
| +32% | +$5.98M | 1.53% | 14 |
|
|
2023
Q2 | $19.8M | Sell |
171,904
-671
| -0.4% | -$76.2K | 1.86% | 10 |
|
|
2023
Q1 | $18.4M | Sell |
172,575
-33,403
| -16% | -$3.61M | 1.91% | 9 |
|
|
2022
Q4 | $22.9M | Buy |
205,978
+188,073
| +1,050% | +$19.2M | 2.47% | 3 |
|
|
2022
Q3 | $1.54M | Sell |
17,905
-466
| -3% | -$41.6K | 0.55% | 46 |
|
|
2022
Q2 | $1.68M | Buy |
18,371
+46
| +0.3% | +$4.08K | 0.55% | 45 |
|
|
2022
Q1 | $1.5M | Buy |
18,325
+440
| +2% | +$34.7K | 0.42% | 64 |
|
|
2021
Q4 | $1.37M | Sell |
17,885
-2,905
| -14% | -$231K | 0.52% | 36 |
|
|
2021
Q3 | $1.56M | Buy |
20,790
+37
| +0.2% | +$2.81K | 0.71% | 31 |
|
|
2021
Q2 | $1.61M | Sell |
20,753
-941
| -4% | -$70K | 0.73% | 32 |
|
|
2021
Q1 | $1.6M | Buy |
21,694
+37
| +0.2% | +$2.73K | 0.78% | 28 |
|
|
2020
Q4 | $1.69M | Sell |
21,657
-485
| -2% | -$37.1K | 0.84% | 24 |
|
|
2020
Q3 | $1.75M | Sell |
22,142
-815
| -4% | -$63.8K | 1.02% | 19 |
|
|
2020
Q2 | $1.69M | Buy |
22,957
+369
| +2% | +$27.8K | 1.07% | 17 |
|
|
2020
Q1 | $1.66M | Buy |
22,588
+34
| +0.2% | +$2.67K | 1.13% | 17 |
|
|
2019
Q4 | $1.96M | Sell |
22,554
-438
| -2% | -$36K | 1.42% | 18 |
|
|
2019
Q3 | $1.85M | Buy |
22,992
+454
| +2% | +$36.4K | 1.54% | 16 |
|
|
2019
Q2 | $1.8M | Buy |
22,538
+6,487
| +40% | +$497K | 1.53% | 17 |
|
|
2019
Q1 | $1.27M | Sell |
16,051
-789
| -5% | -$59K | 1.15% | 19 |
|
|
2018
Q4 | $1.23M | Sell |
16,840
-231
| -1% | -$16.3K | 1.12% | 20 |
|
|
2018
Q3 | $1.16M | Sell |
17,071
-662
| -4% | -$42.2K | 0.97% | 18 |
|
|
2018
Q2 | $1.03M | Sell |
17,733
-15
| -0.1% | -$846 | 0.9% | 20 |
|
|
2018
Q1 | $922K | Sell |
17,748
-1,989
| -10% | -$107K | 0.84% | 18 |
|
|
2017
Q4 | $1.21M | Hold |
19,737
| – | – | 1.58% | 13 |
|
|
2017
Q3 | $1.21M | Sell |
19,737
-192
| -1% | -$11.6K | 1.26% | 16 |
|
|
2017
Q2 | $1.22M | Buy |
19,929
+481
| +2% | +$29.3K | 1.38% | 15 |
|
|
2017
Q1 | $1.18M | Buy |
19,448
+574
| +3% | +$34.8K | 1.21% | 16 |
|
|
2016
Q4 | $1.06M | Buy |
+18,874
| New | +$1.1M | 1.08% | 21 |
|
Other funds holding MRK
VCM
VPM
Bryn Mawr Capital Management's MRK Position: Q1 2026 in Review
Bryn Mawr Capital Management reduced its Merck (MRK) stake by 3.5% in Q1 2026, selling an estimated $943K and leaving 222,405 shares worth $26.8M. The position accounts for 1.3% of the portfolio, ranked #12.
Bryn Mawr Capital Management first reported a position in MRK in Q4 2016 and has held it in 38 quarters since. The position peaked at $32.6M in Q1 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Bryn Mawr Capital Management held 222,405 shares of Merck worth $26.8M as of Q1 2026.
- Bryn Mawr Capital Management sold 8,169 Merck shares in Q1 2026, an estimated $943K.
- Merck made up 1.3% of Bryn Mawr Capital Management's portfolio in Q1 2026, its #12 holding.
- Bryn Mawr Capital Management first reported a position in Merck in Q4 2016 and has held it in 38 quarters since.
- Bryn Mawr Capital Management's Merck position peaked at $32.6M in Q1 2024.
- 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Bryn Mawr Capital Management's 13F filing for Q1 2026, filed 4 May 2026.